Context Therapeutics Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The company is a pre-revenue biopharmaceutical developer focused on solid tumors. Its lead candidate, preclinical CTIM-76, is a CLDN6×CD3 bispecific antibody. The company discontinued ONA-XR development in 2023 and is concentrating resources on CTIM-76.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $17.8 million | $7.1 million |
| General and administrative expense | $7.3 million | $7.8 million |
| Operating loss | $25.1 million | $15.4 million |
| Net loss | $24.0 million | $14.8 million |
| Net loss per share, basic and diluted | $1.50 | $0.93 |
| Cash used in operating activities | $21.0 million | $13.5 million |
| Cash and cash equivalents at year-end | $14.4 million | $35.5 million |
FY2023 R&D increased 151%, principally as CTIM-76 manufacturing and IND-enabling work advanced; ONA-XR spending declined following its discontinuation. G&A fell 6%. Interest income was $1.2 million, up from $0.5 million. No product revenue, gross margin, or product-sales outlook is reported. Year-end total current assets were $16.0 million and current liabilities were $4.2 million. The filing reports no debt.
Cash declined by $21.0 million during 2023. Management said cash was expected to fund operations into late 2024, but also concluded that available cash was insufficient to fund projected operations for at least 12 months from the March 21, 2024 financial-statement issuance date. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. The company has no credit facility or committed financing.
Business developments, outlook, and risks
- At filing, CTIM-76 IND-enabling studies were ongoing. The company expected to submit an IND by the end of March 2024 and, subject to FDA clearance, planned a Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers. These were plans, not reported completed milestones.
- In March 2023, Context discontinued ONA-XR development and wound down its clinical trials, citing financing-market conditions, competition, study findings, and other factors. It planned to explore strategic options for ONA-XR; it reported no expected future material program expenses.
- A February 29, 2024 amendment to the Integral license narrowed the license to CTIM-76 and reduced aggregate development/regulatory milestones from $55 million to $15 million, sales milestones from $130 million to $12.5 million, and royalties from 8–12% to 6% beginning no sooner than February 1, 2034.
- Context disclosed potentially relevant third-party patents expiring in January 2034 that may cover aspects of CTIM-76. It believes it has defenses but may not prevail or obtain a license on acceptable terms.
- Preclinical CTIM-76 results described in the filing are not clinical evidence; the company cautions that preclinical and early data may not predict later outcomes. Development risks include safety, efficacy, regulatory delays, manufacturing and third-party dependence, competition, intellectual-property challenges, and financing availability.
- Management expects continued losses and increased development costs. Additional capital will be required; financing could dilute shareholders, impose restrictions, or require licensing or surrendering rights. The company had five full-time employees as of March 1, 2024 and relies on external manufacturers and service providers.
Other notable facts
Total assets were $16.1 million and stockholders’ equity was $11.9 million at December 31, 2023. The company had 15,966,053 common shares outstanding at year-end and reported the same count as of March 19, 2024. It reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation, consistent with the company’s emerging-growth-company exemption. The financial-statement audit opinion was unqualified, with a going-concern explanatory paragraph.
Important facts for investors to verify
- Whether additional financing is secured, on what terms, and how long it extends the cash runway; reconcile the “late 2024” runway statement with the going-concern conclusion.
- Whether the CTIM-76 IND was submitted and cleared, and whether the Phase 1 trial began; confirm actual timing, scope, and funding.
- Current clinical and manufacturing progress, including any safety findings and the reliability and comparability of the cited preclinical data.
- The status and potential impact of third-party patent rights, and whether any license, dispute, or additional payment is required.
- Any strategic resolution for ONA-XR and the company’s resulting development priorities and remaining obligations.